HUP0202525A2 - Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit - Google Patents

Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit

Info

Publication number
HUP0202525A2
HUP0202525A2 HU0202525A HUP0202525A HUP0202525A2 HU P0202525 A2 HUP0202525 A2 HU P0202525A2 HU 0202525 A HU0202525 A HU 0202525A HU P0202525 A HUP0202525 A HU P0202525A HU P0202525 A2 HUP0202525 A2 HU P0202525A2
Authority
HU
Hungary
Prior art keywords
ifn
peg
medicaments
kit
alpha
Prior art date
Application number
HU0202525A
Other languages
English (en)
Inventor
Mary Catherine Graves
Stephen Christopher Pappas
Friederike Zahm
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of HUP0202525A2 publication Critical patent/HUP0202525A2/hu
Publication of HUP0202525A3 publication Critical patent/HUP0202525A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgya IFN-a vagy PEG-IFN-a gyógyászatilag hatékonymennyisége és a mikofenolsav gyógyászatilag alkalmas sója vagyelőgyógyszere gyógyászatilag hatékony mennyisége együttesfelhasználása májbetegségek kezelésére. A komponenseket legalább olyanidőtartamon át adagolják, hogy a betegek perifériás vérében 24 héttela kezelés befejezése után a HCV-RNS mennyiség 100 kópia/ml érték alácsökkenjen. Ó
HU0202525A 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-alpha, medicaments and kit comprising thereof HUP0202525A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (2)

Publication Number Publication Date
HUP0202525A2 true HUP0202525A2 (hu) 2002-11-28
HUP0202525A3 HUP0202525A3 (en) 2003-11-28

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202525A HUP0202525A3 (en) 1999-08-13 2000-08-08 Mycophenolate mofetil in association with peg-ifn-alpha, medicaments and kit comprising thereof

Country Status (14)

Country Link
EP (1) EP1220683A2 (hu)
JP (1) JP2003507339A (hu)
CN (1) CN1368887A (hu)
AU (1) AU7408200A (hu)
BR (1) BR0013252A (hu)
CA (1) CA2380653A1 (hu)
HU (1) HUP0202525A3 (hu)
MX (1) MXPA02001296A (hu)
PE (1) PE20010490A1 (hu)
PL (1) PL357367A1 (hu)
RU (1) RU2002105485A (hu)
TR (1) TR200200401T2 (hu)
WO (1) WO2001012214A2 (hu)
ZA (1) ZA200200280B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
SI1719773T1 (sl) 2004-02-24 2009-08-31 Japan Tobacco Inc Kondenzirane heterotetraciklične spojine in njihova uporaba kot inhibitorji polimeraze HCV
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
MX2007001663A (es) 2004-08-12 2007-04-10 Schering Corp Formulacion de interferon pegilado estable.
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP2412730B1 (en) * 2009-03-27 2014-09-10 JW Pharmaceutical Corporation Interferon-alpha (ifn-alpha ) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp)
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN107530403A (zh) * 2014-11-06 2018-01-02 药华医药股份有限公司 用于长效型干扰素的剂量方案
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
PL357367A1 (en) 2004-07-26
HUP0202525A3 (en) 2003-11-28
ZA200200280B (en) 2003-04-11
WO2001012214A3 (en) 2001-10-04
MXPA02001296A (es) 2002-07-22
CA2380653A1 (en) 2001-02-22
CN1368887A (zh) 2002-09-11
EP1220683A2 (en) 2002-07-10
TR200200401T2 (tr) 2002-06-21
BR0013252A (pt) 2002-04-16
RU2002105485A (ru) 2004-01-27
WO2001012214A2 (en) 2001-02-22
PE20010490A1 (es) 2001-04-27
AU7408200A (en) 2001-03-13
JP2003507339A (ja) 2003-02-25

Similar Documents

Publication Publication Date Title
LU90392I2 (fr) Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
BR0010498A (pt) Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
IL112667A (en) 6-substituted derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
RU92004521A (ru) Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения
ATE326867T1 (de) Freie aminosäure enthaltende zusammensetzung
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
DE69002718D1 (de) Medikamente.
FR2721516B1 (fr) Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation.
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
KR970061244A (ko) 치매 치료용 약학 조성물
JP2003514025A5 (hu)
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
BR0114339A (pt) Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
DE60202299D1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
ECSP003616A (es) Micofenolato mofetil en asociacion con peg-ifn-alfa